DelveInsight's "Chronic Pain Associated with Painful Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Chronic Pain Associated with Painful Diabetic Neuropathy Market, historical and forecasted epidemiology, the pipeline insight as well as the Chronic Pain Associated with Painful Diabetic Neuropathy market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Chronic Pain Associated with Painful Diabetic Neuropathy market report also covers emerging drugs, current treatment practices, Chronic Pain Associated with Painful Diabetic Neuropathy market shares of the individual therapies, current and forecasted Chronic Pain Associated with Painful Diabetic Neuropathy Market Size segmented by seven major markets.
Painful diabetic neuropathy (PDN) is a well-known complication of diabetes and the most common cause of all neuropathic pain. About one-third of all diabetes patients suffer from PDN. It is defined as the presence of signs and symptoms of nerve dysfunction in patients with diabetes mellitus after the exclusion of other causes.
According to a study conducted by Veves et al. (2008), the epidemiology of PDN has not been well established and based on available data, the prevalence of pain is 10–20% in patients with diabetes and from 40–50% in those with diabetic neuropathy. As per Pesaresi et al. (n.d.)., males develop neuropathy earlier than females, and PDN is more frequent in men than in women.
As per Ziegler (2009), chronic neuropathic pain is present in 13–26% of diabetic patients. From a survey in Augsburg, Germany, the prevalence of painful polyneuropathy was found to be 13.3% in diabetic Subjects.
Chronic Pain Associated with Painful Diabetic Neuropathy Market Growth Analysis
Increased awareness of this unique histology has allowed for the development of specific drugs specific to PDN and has begun to shed light on the similarities and possible unique aspects of PDN. These factors, along with the expected launch of emerging therapies, will boost the Chronic Pain Associated with Painful Diabetic Neuropathy Market Size Growth in the forecast period.
The Chronic Pain Associated with Painful Diabetic Neuropathy market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Pain Associated with Painful Diabetic Neuropathy market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Chronic Pain Associated with Painful Diabetic Neuropathy market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology Forecast
The Chronic Pain Associated with Painful Diabetic Neuropathy epidemiology section covers insights about historical and current Chronic Pain Associated with Painful Diabetic Neuropathy patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognise the causes of current and forecasted Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Some of the key players at the global level are developing therapies to treat Chronic Pain Associated with Painful Diabetic Neuropathy (PDN). Several potential therapies are under investigation. These include newer agents, which are undergoing evaluation in chronic pain associated with PDN. Chronic Pain Associated with Painful Diabetic Neuropathy Companies includes NeuroMetrix, AstraZeneca, Highland Instruments, Nevro Corp, and many others.
Chronic Pain Associated with Painful Diabetic Neuropathy Therapies covered in the report includes HF10 Therapy, Active tDCS + Active TUS, MEDI7352, SENSUS, and many more.
For more details, visit: Chronic Pain Associated with Painful Diabetic Neuropathy Market Growth